Philips and Hansen Medical to Integrate X-Ray Imaging and Robotic Catheter to Advance Treatment of Irregular Heartbeats
15 1월 2009 - 2:00AM
Marketwired
Royal Philips Electronics and Hansen Medical, Inc. (NASDAQ: HNSN)
today announced that they have signed joint development and
cooperation agreements to co-develop integrated products that may
simplify complex cardiac procedures to diagnose and treat irregular
heartbeats, also known as arrhythmias.
Cardiac arrhythmias can drastically reduce the quality of life
and can also lead to serious health risks including heart failure
and stroke. Nearly 550,000 new patients are diagnosed with cardiac
arrhythmias in the United States each year and arrhythmias cause
approximately 250,000 deaths annually according to the Heart Rhythm
Foundation and the American College of Cardiology. The condition
also affects over 4.5 million people in Europe.
The agreements will enable the creation of integrated product
solutions by combining Philips' Allura Xper X-Ray system with
Hansen Medical's Sensei� Robotic Catheter System. The resulting
innovations will seek to enable electrophysiologists to perform
complex procedures with greater confidence and improved
efficiency.
"This agreement is an important step in the development of our
dedicated electrophysiology business program," said Gerard Winkels,
vice president and general manager, Electrophysiology for Philips
Healthcare. "By collaborating with best-in-class companies such as
Hansen Medical, we're able to develop comprehensive solutions
designed around the needs of the electrophysiologist."
"We are very pleased about the relationship we have with
Philips," said Gary Restani, president and COO of Hansen Medical.
"We believe that combining our efforts will allow us to provide
enhanced value and improved capabilities to our customers as this
alliance is targeted at developing integrated solutions that will
impact not only visualization, but also instinctive driving within
3D anatomical models."
The Sensei system allows physicians to place mapping catheters
in hard-to-reach anatomical locations within the heart easily,
accurately and with stability during cardiac arrhythmia
procedures.
The Philips' integrated EP lab system combines the proven Allura
Xper X-Ray family with specifically designed innovations like EP
cockpit and EP navigator to improve the lab environment,
facilitating complex procedures and integrating the EP workflow
process.
About Hansen Medical, Inc.
Hansen Medical, Inc., based in Mountain View, Calif., develops
products and technology using robotics for the accurate
positioning, manipulation and control of catheters and
catheter-based technologies. Its first product, the Sensei� Robotic
Catheter system, is a robotic navigation system that enables
clinicians to place mapping catheters in hard-to-reach anatomical
locations within the heart easily, accurately and with stability
during complex cardiac arrhythmia procedures. The Sensei system is
compatible with fluoroscopy, ultrasound, 3D surface map and patient
electrocardiogram data and was cleared by the U.S. Food and Drug
Administration (FDA) in May 2007 for manipulation and control of
certain mapping catheters in Electrophysiology (EP) procedures. The
safety and effectiveness of the Sensei system for use with cardiac
ablation catheters in the treatment of cardiac arrhythmias,
including atrial fibrillation (AF), have not been established. The
Sensei system is CE Marked for use during EP procedures, such as
guiding catheters in the treatment of AF. Additional information
can be found at www.hansenmedical.com.
Forward-Looking Statements
This press release contains forward-looking statements
regarding, among other things, statements relating to expectations,
goals, plans, objectives and future events. Hansen Medical intends
such forward-looking statements to be covered by the safe harbor
provisions for forward-looking statements contained in Section 21E
of the Exchange Act and the Private Securities Litigation Reform
Act of 1995. Examples of such statements include statements about
the creation of integrated products and the resulting benefits of
such products. These statements are based on the current estimates
and assumptions of Hansen Medical management as of the date of this
press release and are subject to risks, uncertainties, changes in
circumstances, assumptions and other factors that may cause actual
results to differ materially from those indicated by
forward-looking statements. Important factors that could cause
actual results to differ materially from those indicated by such
forward-looking statements include, among others, the risks and
uncertainties inherent in Hansen Medical's business, including
potential safety and regulatory issues that could slow or suspend
its sales; its ability to effectively sell, service and support its
products; the scope and validity of intellectual property rights
applicable to its products; competition from other companies; and
its ability to obtain additional financing to support its
operations. These and other risks are described in greater detail
under the heading "Risk Factors" contained in Hansen Medical's
periodic SEC filings, including its Quarterly Report on Form 10-Q
filed with the SEC on November 5, 2008. Given these uncertainties,
you should not place undue reliance on these forward-looking
statements. Hansen Medical undertakes no obligation to revise or
update information herein to reflect events or circumstances in the
future, even if new information becomes available.
Sensei, IntelliSense, Hansen Medical and Heart Logo and Hansen
Medical Heart Logo are registered trademarks and Artisan and
CoHesion are trademarks of Hansen Medical, Inc. in the United
States and other countries.
Media inquiries, please contact: Philips Healthcare North
America Ian Race Tel: +1 978 659 4624 Email: Email Contact EMEA
Mark Groves Tel: +31 653 179 850 Email: Email Contact Hansen
Medical Amy Cook Tel: +1 925 552 7893 Email: Email Contact
Hansen Medical, Inc. (MM) (NASDAQ:HNSN)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Hansen Medical, Inc. (MM) (NASDAQ:HNSN)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024